TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Peijia Medical Ltd. ( (HK:9996) ) is now available.
Peijia Medical Ltd. reported a 17.3% increase in revenue for the first half of 2025, driven by robust sales growth in its TAVR and neurointerventional businesses. The company achieved significant market share gains in China’s transfemoral TAVR market and launched new premium products, contributing to a 24.0% rise in TAVR-related sales. Neurointerventional product sales also grew by 12.2%, supported by market penetration of existing products and the introduction of the YonFlow Flow Diverting Stent. Operational efficiency improvements led to a 42.4% increase in the Neurointerventional Business segment profit and a narrowing of losses in the Transcatheter Valve Therapeutic Business. Overall, Peijia Medical’s strategic initiatives and market education efforts have strengthened its position as a leading TAVR brand in China.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Ltd. operates in the medical device industry, focusing on the development and sale of products for valvular heart diseases and cerebrovascular diseases. The company is known for its Transcatheter Aortic Valve Replacement (TAVR) products and neurointerventional devices, with a strong market presence in China.
Average Trading Volume: 2,212,986
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.01B
See more data about 9996 stock on TipRanks’ Stock Analysis page.